Unicycive Therapeutics Inc Cash Flow-to-Debt Ratio
Unicycive Therapeutics Inc cash flow-to-debt ratio. Unicycive Therapeutics Inc (UNCY) has a Cash Flow-to-Debt Ratio of -0.41x as of June 2026, meaning its operating cash flow of $-7.60 Million could theoretically repay 0% of its total liabilities ($18.76 Million) in one year. Check Unicycive Therapeutics Inc (UNCY) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Unicycive Therapeutics Inc (2018–2025)
Cash flow-to-debt ratio of Unicycive Therapeutics Inc from 2018 to 2025. Historical debt coverage capacity for Unicycive Therapeutics Inc across 8 annual periods. Also explore UNCY net assets growth trend to track the company's year-over-year net asset growth rate.
Unicycive Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2018–2025)
Unicycive Therapeutics Inc cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Unicycive Therapeutics Inc. For the full cash flow conversion analysis, see cash flow conversion of Unicycive Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.65x | $-31.32 Million | $18.94 Million | ▼ -40.3% |
| 2024 | -1.18x | $-28.57 Million | $24.24 Million | ▼ -16.1% |
| 2023 | -1.02x | $-18.28 Million | $18.00 Million | ▲ +78.7% |
| 2022 | -4.77x | $-15.65 Million | $3.28 Million | ▼ -86.8% |
| 2021 | -2.55x | $-5.77 Million | $2.26 Million | ▼ -402.8% |
| 2020 | -0.51x | $-1.46 Million | $2.88 Million | ▲ +61.0% |
| 2019 | -1.30x | $-1.18 Million | $903.00K | ▼ -107.5% |
| 2018 | -0.63x | $-775.00K | $1.24 Million | — |